Key result
Pravastatin 20 mg/d significantly lowered plasma cholesterol (265 to 218 mg/dL, P<0.01), LDL cholesterol (186 to 145 mg/dL, P<0.03), and apoB levels (168 to 125 mg/dL, P<0.01) in FCHL subjects.
Why the study?
Does pravastatin improve lipoprotein levels and apoB catabolism in patients with familial combined hyperlipidemia?
RCT (n=5)
Double-blind
Randomized
Does pravastatin improve lipoprotein levels and apoB catabolism in patients with familial combined hyperlipidemia?
Absolute Event Rate: 218% vs 265%
p-value: p=<0.01
In a specific kindred with familial combined hyperlipidemia characterized by impaired apoB catabolism, pravastatin effectively lowered atherogenic lipids by increasing the fractional catabolic rate of LDL-apoB.
No takes yet. Share an insight, caveat, or question.
Challenges overproduction-centric FCHL models; leaves open generalizability beyond this single kindred.
Aguilar‐Salinas et al. (1997) conducted an RCT in Familial combined hyperlipidemia (FCHL) (n=5). Pravastatin vs. Placebo was evaluated on Plasma cholesterol (p=<0.01). Pravastatin 20 mg/d significantly lowered plasma cholesterol (265 to 218 mg/dL, P<0.01), LDL cholesterol (186 to 145 mg/dL, P<0.03), and apoB levels (168 to 125 mg/dL, P<0.01) in FCHL subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: